(Q36546255)

14 August 2017

1 reference

title

Assays for pharmacodynamic analysis of histone deacetylase inhibitors (English)

1 reference

14 August 2017

1 reference

4

Jane B Trepel

1 reference

14 August 2017

Eun Joo Chung

1

1 reference

14 August 2017

Min-Jung Lee

series ordinal

2

1 reference

14 August 2017

Sunmin Lee

series ordinal

3

1 reference

14 August 2017

language of work or name

English

0 references

publication date

1 April 2006

1 reference

Expert Opinion on Drug Metabolism & Toxicology

14 August 2017

published in

1 reference

14 August 2017

volume

2

1 reference

14 August 2017

issue

2

1 reference

14 August 2017

page(s)

213-230

1 reference

The language of covalent histone modifications

14 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.2.213

Signaling to chromatin through histone modifications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.2.213

Protein modules that manipulate histone tails for chromatin regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.2.213

Histone acetylation in chromatin structure and transcription

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.2.213

Histone deacetylases as therapeutic targets in hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.2.213

Worms gang up on bacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.2.213

Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.2.213

Histone-deacetylase inhibitors: novel drugs for the treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.2.213

Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.2.213

Histone deacetylase inhibitors: insights into mechanisms of lethality

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.2.213

Histone deacetylase inhibitors in cancer therapy: is transcription the primary target?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.2.213

Acetylation of nuclear receptors in cellular growth and apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.2.213

Targeted histone deacetylase inhibition for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.2.213

Clinical development of histone deacetylase inhibitors as anticancer agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.2.213

Important roles of reversible acetylation in the function of hematopoietic transcription factors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.2.213

Histone Deacetylase Inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.2.213

Histone deacetylase as a new target for cancer chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.2.213

Functional significance of histone deacetylase diversity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.2.213

The human histone deacetylase family

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.2.213

Deacetylase enzymes: biological functions and the use of small-molecule inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.2.213

The histone deacetylase 9 gene encodes multiple protein isoforms

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.2.213

Cloning and functional characterization of HDAC11, a novel member of the human histone deacetylase family

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.2.213

Histone deacetylases (HDACs): characterization of the classical HDAC family

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.2.213

Structural basis for the NAD-dependent deacetylase mechanism of Sir2

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.2.213

Structure and chemistry of the Sir2 family of NAD+-dependent histone/protein deactylases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.2.213

The Sir2 family of protein deacetylases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.2.213

Acetylation of the C terminus of Ku70 by CBP and PCAF controls Bax-mediated apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.2.213

Histone deacetylase inhibitors: understanding a new wave of anticancer agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.2.213

Histone deacetylase inhibitors and cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.2.213

A review of depsipeptide and other histone deacetylase inhibitors in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.2.213

Histone deacetylase inhibitors and cancer: from cell biology to the clinic

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.2.213

Histone deacetylase inhibitors in clinical development

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.2.213

Histone deacetylase inhibitors in programmed cell death and cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.2.213

Epigenetic and chromatin modifiers as targeted therapy of hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.2.213

Prospects: histone deacetylase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.2.213

Chromatin Structure: A Repeating Unit of Histones and DNA

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.2.213

The nucleosomal core histone octamer at 3.1 A resolution: a tripartite protein assembly and a left-handed superhelix

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.2.213

Crystal structure of the nucleosome core particle at 2.8 A resolution

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.2.213

Acetylation of general transcription factors by histone acetyltransferases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.2.213

Histone deacetylase inhibitors: assays to assess effectiveness in vitro and in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.2.213

Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.2.213

A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.2.213

Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.2.213

Assays for the identification and evaluation of histone acetyltransferase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.2.213

High-throughput screening of small molecules in miniaturized mammalian cell-based assays involving post-translational modifications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.2.213

A fluorogenic histone deacetylase assay well suited for high-throughput activity screening

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.2.213

Improved fluorogenic histone deacetylase assay for high-throughput-screening applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.2.213

Subtype selective substrates for histone deacetylases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.2.213

In vitro assays for the determination of histone deacetylase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.2.213

Acetylation: a regulatory modification to rival phosphorylation?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.2.213

Regulation of distinct biological activities of the NF-kappaB transcription factor complex by acetylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.2.213

Distinct interactions of PML-RARalpha and PLZF-RARalpha with co-repressors determine differential responses to RA in APL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.2.213

Molecular pathogenesis of acute promyelocytic leukaemia and APL variants

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.2.213

Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.2.213

Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.2.213

Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.2.213

Transcriptional regulation of the transforming growth factor beta type II receptor gene by histone acetyltransferase and deacetylase is mediated by NF-Y in human breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.2.213

Histone deacetylase (HDAC) inhibitor activation of p21WAF1 involves changes in promoter-associated proteins, including HDAC1

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.2.213

Heat shock protein 90 as a molecular target for cancer therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.2.213

The Hsp90 chaperone complex as a novel target for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.2.213

Hsp90 as a therapeutic target in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.2.213

Altered states: selectively drugging the Hsp90 cancer chaperone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.2.213

HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.2.213

Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.2.213

Regulation of the dynamics of hsp90 action on the glucocorticoid receptor by acetylation/deacetylation of the chaperone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.2.213

Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.2.213

17-Allylamino-17-demethoxygeldanamycin (17-AAG) is effective in down-regulating mutated, constitutively activated KIT protein in human mast cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.2.213

KIT (CD117): a review on expression in normal and neoplastic tissues, and mutations and their clinicopathologic correlation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.2.213

Clonality and molecular pathogenesis of mastocytosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.2.213

What have we learnt from mouse models of NPM-ALK-induced lymphomagenesis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.2.213

Role of VHL gene mutation in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.2.213

Modulation of Akt kinase activity by binding to Hsp90

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.2.213

Activation of AKT kinases in cancer: implications for therapeutic targeting

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.2.213

AKT/PKB signaling mechanisms in cancer and chemoresistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.2.213

Interaction of Hsp90 with the nascent form of the mutant epidermal growth factor receptor EGFRvIII.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.2.213

Epidermal growth factor receptors harboring kinase domain mutations associate with the heat shock protein 90 chaperone and are destabilized following exposure to geldanamycins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.2.213

Mutations and addiction to EGFR: the Achilles 'heal' of lung cancers?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.2.213

Targeting the HER-kinase axis in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.2.213

Normal and oncogenic FLT3

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.2.213

Small molecule FLT3 tyrosine kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.2.213

Selective apoptosis of tandemly duplicated FLT3-transformed leukemia cells by Hsp90 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.2.213

21 January 2018

The Hallmarks of Cancer

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.2.213

Histone deacetylase inhibitors trigger a G2 checkpoint in normal cells that is defective in tumor cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.2.213

Telomerase activity and proliferation index in aggressive mature B-cell lymphoma: comparison to germinal center phenotypic markers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.2.213

Butyrate as a differentiating agent: pharmacokinetics, analogues and current status

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.2.213

A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.2.213

Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.2.213

Evidence of a functional role for p21WAF1/CIP1 down-regulation in synergistic antileukemic interactions between the histone deacetylase inhibitor sodium butyrate and flavopiridol

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.2.213

Enhancement of depsipeptide-mediated apoptosis of lung or esophageal cancer cells by flavopiridol: activation of the mitochondria-dependent death-signaling pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.2.213

Abrogation of p21 expression by flavopiridol enhances depsipeptide-mediated apoptosis in malignant pleural mesothelioma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.2.213

Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.2.213

Histone deacetylases inhibitors as anti-angiogenic agents altering vascular endothelial growth factor signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.2.213

Histone deacetylase inhibitor FK228 inhibits tumor angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.2.213

Modulation of angiogenesis-related protein synthesis by valproic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.2.213

The histone deacetylase inhibitor NVP-LAQ824 inhibits angiogenesis and has a greater antitumor effect in combination with the vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.2.213

The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: issues and recommendations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.2.213

Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer a

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.2.213

Dynamic contrast-enhanced magnetic resonance imaging as a pharmacodynamic measure of response after acute dosing of AG-013736, an oral angiogenesis inhibitor, in patients with advanced solid tumors: results from a phase I study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.2.213

Combination antiangiogenesis therapy with marimastat, captopril and fragmin in patients with advanced cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.2.213

Surrogate markers in antiangiogenesis clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.2.213

Molecular detection and characterization of circulating tumor cells and micrometastases in prostatic, urothelial, and renal cell carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.2.213

Relevance of disseminated tumour cells in blood and bone marrow of patients with solid epithelial tumours in perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.2.213

Detection of disseminated tumor cells in peripheral blood

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.2.213

Circulating tumor cells, disease progression, and survival in metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.2.213

Methods for isolating circulating epithelial cells and criteria for their classification as carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.2.213

Imaging the pharmacodynamics of HER2 degradation in response to Hsp90 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.2.213

21 January 2018

Heat shock protein 90.

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.2.213

Polyubiquitination and proteasomal degradation of the p185c-erbB-2 receptor protein-tyrosine kinase induced by geldanamycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.2.213

New method to detect histone acetylation levels by flow cytometry

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.2.213

Cotreatment with the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) enhances imatinib-induced apoptosis of Bcr-Abl-positive human acute leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.2.213

Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.2.213

p300 and p300/cAMP-response element-binding protein-associated factor acetylate the androgen receptor at sites governing hormone-dependent transactivation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.2.213

Acetylation by PCAF enhances CIITA nuclear accumulation and transactivation of major histocompatibility complex class II genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.2.213

Regulation of E2F1 activity by acetylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.2.213

Acetylation and modulation of erythroid Krüppel-like factor (EKLF) activity by interaction with histone acetyltransferases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.2.213

Direct acetylation of the estrogen receptor alpha hinge region by p300 regulates transactivation and hormone sensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.2.213

Regulation of activity of the transcription factor GATA-1 by acetylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.2.213

CREB-Binding protein acetylates hematopoietic transcription factor GATA-1 at functionally important sites

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.2.213

Functional regulation of GATA-2 by acetylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.2.213

Acetylation of GATA-3 affects T-cell survival and homing to secondary lymphoid organs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.2.213

HIV-1 tat transcriptional activity is regulated by acetylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.2.213

Acetylation regulates transcription factor activity at multiple levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.2.213

Coactivator p300 acetylates the interferon regulatory factor-2 in U937 cells following phorbol ester treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.2.213

A specific lysine in c-Jun is required for transcriptional repression by E1A and is acetylated by p300

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.2.213

Effects of B-Myb on gene transcription: phosphorylation-dependent activity ans acetylation by p300

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.2.213

c-Myb acetylation at the carboxyl-terminal conserved domain by transcriptional co-activator p300.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.2.213

Acetylation of MyoD directed by PCAF is necessary for the execution of the muscle program

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.2.213

Stimulation of NF-E2 DNA binding by CREB-binding protein (CBP)-mediated acetylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.2.213

Enhancement of nuclear factor-kappa B acetylation by coactivator p300 and HIV-1 Tat proteins.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.2.213

Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.2.213

DNA damage activates p53 through a phosphorylation-acetylation cascade

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.2.213

p53 sites acetylated in vitro by PCAF and p300 are acetylated in vivo in response to DNA damage

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.2.213

Duration of nuclear NF-kappaB action regulated by reversible acetylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.2.213

Transcription factor Sp3 is regulated by acetylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.2.213

Cooperation of the transcriptional coactivators CBP and p300 with Stat6

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.2.213

Acetylation by histone acetyltransferase CREB-binding protein/p300 of STAT6 is required for transcriptional activation of the 15-lipoxygenase-1 gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.2.213

Acetylation of TAF(I)68, a subunit of TIF-IB/SL1, activates RNA polymerase I transcription

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.2.213

P/CAF-mediated acetylation regulates the function of the basic helix-loop-helix transcription factor TAL1/SCL

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.2.213

Competitive recruitment of CBP and Rb-HDAC regulates UBF acetylation and ribosomal transcription

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.2.213

Regulation of transcription factor YY1 by acetylation and deacetylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.2.213

In vitro acetylation of HMGB-1 and -2 proteins by CBP: the role of the acidic tail

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.2.213

Acetylation of novel sites in the nucleosomal binding domain of chromosomal protein HMG-14 by p300 alters its interaction with nucleosomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.2.213

Specific acetylation of chromosomal protein HMG-17 by PCAF alters its interaction with nucleosomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.2.213

Acetylation of HMG I(Y) by CBP turns off IFN beta expression by disrupting the enhanceosome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.2.213

Regulation of hormone-induced histone hyperacetylation and gene activation via acetylation of an acetylase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.2.213

Acetylation of beta-catenin by CREB-binding protein (CBP).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.2.213

Acetylation of histones and transcription-related factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.2.213

p300-mediated acetylation of human transcriptional coactivator PC4 is inhibited by phosphorylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.2.213

Regulation of human flap endonuclease-1 activity by acetylation through the transcriptional coactivator p300

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.2.213

Acetylation of importin-alpha nuclear import factors by CBP/p300.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.2.213

The post-translational modifications of proliferating cell nuclear antigen: acetylation, not phosphorylation, plays an important role in the regulation of its function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.2.213

Hsp90 inhibition depletes Chk1 and sensitizes tumor cells to replication stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.2.213

Hypoxia-induced activation of HIF-1: role of HIF-1alpha-Hsp90 interaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.2.213

Stabilization of integrin-linked kinase by binding to Hsp90.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.2.213

Mutant conformation of p53 translated in vitro or in vivo requires functional HSP90.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.2.213

Heat-shock protein hsp90 governs the activity of pp60v-src kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.2.213

Destabilization of Raf-1 by geldanamycin leads to disruption of the Raf-1-MEK-mitogen-activated protein kinase signalling pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.2.213

The hsp90-binding antibiotic geldanamycin decreases Raf levels and epidermal growth factor signaling without disrupting formation of signaling complexes or reducing the specific enzymatic activity of Raf kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.2.213

Association of the heat shock protein hsp90 with steroid hormone receptors and tyrosine kinase oncogene products

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.2.213

Regulation of survivin function by Hsp90

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.2.213

Functional requirement of p23 and Hsp90 in telomerase complexes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.2.213

Regulation of NF-κB Action by Reversible Acetylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.2.213

21 January 2018

Identifiers

DOI

10.1517/17425255.2.2.213

1 reference

14 August 2017

1 reference